• support@madhedgefundtrader.com
  • Member Login
Mad Hedge Fund Trader
  • Home
  • About
  • Store
  • Luncheons
  • Testimonials
  • Contact Us
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu

Post-Pandemic Stocks To Diversify Your Portfolio

Biotech Letter

The biotechnology sector had been starved for love on Wall Street for the past few years despite the life-changing research and the introduction of fresh and innovative treatments for previously incurable conditions.
A year ago, the sector had the lowest price earnings multiple with the fastest earnings growth.

That couldn’t last.

With the outbreak of the catastrophic coronavirus disease (COVID-19) pandemic the public has fallen in love with the sector. While the biotechnology sector tanked in March with everything else, several industry benchmarks have been outperforming the broader market so far.

The harsh truth is that cures and vaccines remain far off.

The biotech sector is likely to become the next decade’s largest growth story.

The key is to find companies with strong balance sheets along and leadership that can manage any financial storm.

Nonetheless, there are biotech companies worth considering now, particularly those selling at bargain bin prices but with mature pipelines and promising soon-to-launch commercial products.

One compelling stock for long-term holding is Blueprint Medicines (BPMC).

This company develops targeted medicines for rare genetic types of cancer. So far, Blueprint has three treatments lined up for release in the market in the next 18 months. Just last month, the company announced the FDA approval of its first-ever cancer drug Ayavakit.

Ayavakit, which will be marketed as a treatment for a rare, genetically linked kind of gastrointestinal cancer, comes with a jaw-dropping price tag of $32,000 for a 30-day supply.

This cost is twice the amount of what was originally forecasted. However, analysts claim that this price is “justifiable” considering Ayavakit’s effectiveness and the absence of competition.

Riding the momentum of Ayavakit’s FDA approval, Blueprint has already filed for a second application in a bid to expand the indication for the drug to include patients suffering from gastrointestinal stromal tumors who already underwent three other treatments but failed.

According to the World Health Organization, 5,000 to 6,000 Americans are diagnosed with these tumors every year. Blueprint believes there's a strong chance this gets approved since 86% of their participants in the clinical trial responded to the drug.

Another potential blockbuster for Blueprint is a lung cancer drug currently dubbed as Pralsetinib. If the company gets approved, it can tap into a lucrative market as lung cancer comprises almost 25% of all cancer diagnoses.

Despite the COVID-induced economic crisis, Blueprint remains an attractive investment since it raised money prior to the pandemic. That means the company is well-capitalized.

Admittedly, the stock has gone down by 42% since its July 2019 high and only trades for $57 these days.

Although the company may experience disruptions in the near term, it’s undeniable that patients will still need their medications. Hence, business will definitely come back.

Another scenario is that Blueprint attracts more attention from aggressive acquirers.

So, if you’re looking into how to maximize this opportunity, keep it in mind that your reward all depends on the size of the position you plan to take.

Obviously, this stock comes with its own risks so it might not be an attractive option as a cornerstone of your portfolio. However, adding it to your diversified portfolio could offer you with market-beating returns in the long run.

Another stock that has been disrupted but still presents enticing rewards in the post-COVID days is Invitae (NVTA).

It peaked around February at $28 but went down to trade at a measly $9 to $12 as the coronavirus situation worsened. In fact, Invitae shares bottomed sometime in March at around $7. Since then, investors have been snapping it up at this low price.

Invitae offers genetic testing for kids with developmental issues, so you can easily see why the company isn’t going out of business anytime soon.

Fueling investors’ enthusiasm on this biotech stock are the series of acquisitions it made recently, with the company pouring money on virtual medicine.

In a way, you can say that Invitae is actually quite prepared for what’s happening today.

Just last month, Invitae acquired Orbicule BV otherwise known as Diploid. This recently acquired company develops an AI software that analyzes next-generation sequencing data combined with a patient’s information in order to diagnose genetic disorders.

The terms had Invitae buy 2,800,623 shares of Diploid’s common stock plus roughly $32 million in cash.

In April, Invitae acquired two companies.

One is YouScript Incorporated, which offers clinical decision support and functions as an analytics platform. This deal consisted of 2,293,452 shares of common stock plus $25 million in cash.

The second is Genetic Solutions, operating under the name Genelex, which is a precision medicine company.

With these acquisitions, Invitae needed to raise capital at a bargain-basement price. Does that mean that this genetic testing stock bottomed out?

That’s highly unlikely, but it’s virtually impossible to time market peaks and troughs anyway. The only reasonable means to deal with the current situation is to adopt a long-term mindset.

Keep in mind that this coronavirus pandemic will eventually pass. When it does, the biotechnology industry will return to growth.

After all, the revolutionary and groundbreaking drugs developed by this sector are critical.

For any growth investor on the lookout for high-value and sustainable options, the biotech industry can turn out to be the most lucrative one out there.

 

 

Share this entry
  • Share on Facebook
  • Share on X
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share by Mail
https://www.madhedgefundtrader.com/wp-content/uploads/2020/04/nvtae.png 225 225 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2020-04-23 10:00:082020-04-23 16:17:15Post-Pandemic Stocks To Diversify Your Portfolio

tastytrade, Inc. (“tastytrade”) has entered into a Marketing Agreement with Mad Hedge Fund Trader (“Marketing Agent”) whereby tastytrade pays compensation to Marketing Agent to recommend tastytrade’s brokerage services. The existence of this Marketing Agreement should not be deemed as an endorsement or recommendation of Marketing Agent by tastytrade and/or any of its affiliated companies. Neither tastytrade nor any of its affiliated companies is responsible for the privacy practices of Marketing Agent or this website. tastytrade does not warrant the accuracy or content of the products or services offered by Marketing Agent or this website. Marketing Agent is independent and is not an affiliate of tastytrade. 

Legal Disclaimer

There is a very high degree of risk involved in trading. Past results are not indicative of future returns. MadHedgeFundTrader.com and all individuals affiliated with this site assume no responsibilities for your trading and investment results. The indicators, strategies, columns, articles and all other features are for educational purposes only and should not be construed as investment advice. Information for futures trading observations are obtained from sources believed to be reliable, but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. Your use of the trading observations is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. You must assess the risk of any trade with your broker and make your own independent decisions regarding any securities mentioned herein. Affiliates of MadHedgeFundTrader.com may have a position or effect transactions in the securities described herein (or options thereon) and/or otherwise employ trading strategies that may be consistent or inconsistent with the provided strategies.

Copyright © 2025. Mad Hedge Fund Trader. All Rights Reserved. support@madhedgefundtrader.com
  • Privacy Policy
  • Disclaimer
  • FAQ
Link to: April 23, 2020 - MDT Pro Tips A.M. Link to: April 23, 2020 - MDT Pro Tips A.M. April 23, 2020 - MDT Pro Tips A.M. Link to: April 23, 2020 Link to: April 23, 2020 April 23, 2020
Scroll to top